Literature DB >> 19261620

Comparison of myocardial deformation and velocity dyssynchrony for identification of responders to cardiac resynchronization therapy.

Donato Mele1, Tiziano Toselli, Fabio Capasso, Giuseppe Stabile, Marcello Piacenti, Massimo Piepoli, Sara Giatti, Catherine Klersy, Luciano Sallusti, Roberto Ferrari.   

Abstract

AIMS: It is unclear whether myocardial velocity or deformation indices of dyssynchrony are better at predicting response to cardiac resynchronization therapy (CRT). Therefore, two indices of left ventricular (LV) dyssynchrony based on myocardial velocity and deformation were compared to predict success of CRT. METHODS AND
RESULTS: Sixty patients with dilated cardiomyopathy, New York Heart Association class III-IV, LV ejection fraction (EF) < or =35%, QRS >120 ms underwent CRT. The standard deviation of the averaged time-to-peak longitudinal negative strain (Tepsilon-SD) and positive systolic velocity (Tv-SD) of 12 LV segments were calculated before and after 6 months of CRT. Responders were defined at month 6 by > or =20% EF increase and/or > or =15% end-systolic volume (ESV) decrease with respect to baseline. On univariable analysis, baseline Tepsilon-SD and Tv-SD were both significantly associated with CRT response; however, the area under the receiver operating characteristic curve was better for Tepsilon-SD. On bivariable analysis, only Tepsilon-SD retained an independent prognostic value for CRT response. Results of the analysis did not change when the logistic models were adjusted for aetiology.
CONCLUSION: Baseline dyssynchrony of longitudinal myocardial peak deformation (Tepsilon-SD) appears to be better than dyssynchrony of longitudinal myocardial peak systolic velocities (Tv-SD) for the identification of CRT responders.

Entities:  

Mesh:

Year:  2009        PMID: 19261620     DOI: 10.1093/eurjhf/hfp032

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  7 in total

Review 1.  Current role of echocardiography in cardiac resynchronization therapy.

Authors:  Donato Mele; Matteo Bertini; Michele Malagù; Marianna Nardozza; Roberto Ferrari
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 2.  Longitudinal and circumferential strain in patients with regional LV dysfunction.

Authors:  Manish Bansal; Partho P Sengupta
Journal:  Curr Cardiol Rep       Date:  2013-03       Impact factor: 2.931

3.  It's time for a paradigm shift in the quantitative evaluation of left ventricular dyssynchrony.

Authors:  Brandon K Fornwalt; Jana G Delfino; William W Sprague; John N Oshinski
Journal:  J Am Soc Echocardiogr       Date:  2009-06       Impact factor: 5.251

Review 4.  Recent advances in echocardiography: strain and strain rate imaging.

Authors:  Oana Mirea; Jurgen Duchenne; Jens-Uwe Voigt
Journal:  F1000Res       Date:  2016-04-29

Review 5.  Left Ventricular Deformation and Vortex Analysis in Heart Failure: From Ultrasound Technique to Current Clinical Application.

Authors:  Simona Sperlongano; Antonello D'Andrea; Donato Mele; Vincenzo Russo; Valeria Pergola; Andreina Carbone; Federica Ilardi; Marco Di Maio; Roberta Bottino; Francesco Giallauria; Eduardo Bossone; Paolo Golino
Journal:  Diagnostics (Basel)       Date:  2021-05-17

Review 6.  Optimal site selection and image fusion guidance technology to facilitate cardiac resynchronization therapy.

Authors:  Benjamin J Sieniewicz; Justin Gould; Bradley Porter; Baldeep S Sidhu; Jonathan M Behar; Simon Claridge; Steve Niederer; Christopher A Rinaldi
Journal:  Expert Rev Med Devices       Date:  2018-07-30       Impact factor: 3.166

7.  The effect of iron deficiency on cardiac resynchronization therapy: results from the RIDE-CRT Study.

Authors:  Philipp Lacour; Phi Long Dang; Daniel Armando Morris; Abdul Shokor Parwani; Wolfram Doehner; Franziska Schuessler; Felix Hohendanner; Frank R Heinzel; Andrea Stroux; Carsten Tschoepe; Wilhelm Haverkamp; Leif-Hendrik Boldt; Burkert Pieske; Florian Blaschke
Journal:  ESC Heart Fail       Date:  2020-03-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.